StockData
PharmaCyte Biotech, Inc. logo

PharmaCyte Biotech, Inc. (PMCB) stock

PMCBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 14, 2026Score 6/30
$5.42−0.15 (-2.69%)

Close on Nov 17, 2026Market cap $58.19MP/E –Yield –

PharmaCyte Biotech operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

PharmaCyte Biotech's operating cash flow for the twelve months ending Apr 30, 2026 was -$5.15M. For fiscal 2026 it was -$5.15M. The highest annual figure on record is -$225.23K in fiscal 2011.

Annual operating cash flow

PeriodPeriod endValueChange
FY2026Apr 30, 2026-$5.15M–
FY2025Apr 30, 2025-$2.98M–
FY2024Apr 30, 2024-$2.15M–
FY2023Apr 30, 2023-$3.79M–
FY2022Apr 30, 2022-$4.12M–
FY2021Apr 30, 2021-$3.33M–
FY2020Apr 30, 2020-$2.34M–
FY2019Apr 30, 2019-$2.88M–
FY2018Apr 30, 2018-$5.08M–
FY2017Apr 30, 2017-$3.34M–
FY2016Apr 30, 2016-$4.35M–
FY2015Apr 30, 2015-$4.56M–
FY2014Apr 30, 2014-$1.55M–
FY2013Apr 30, 2013-$390.43K–
FY2012Apr 30, 2012-$259.29K–
FY2011Apr 30, 2011-$225.23K–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ2 2026Jul 31, 2026-$780.89K–
Q4 FY2026CQ1 2026Apr 30, 2026-$1.39M–
Q3 FY2026CQ4 2025Jan 31, 2026-$786.85K–
Q4 FY2025CQ1 2025Apr 30, 2025-$1.04M–
Q3 FY2025CQ4 2024Jan 31, 2025-$509.89K–
Q2 FY2025CQ3 2024Oct 31, 2024-$1.05M–
Q1 FY2025CQ2 2024Jul 31, 2024-$373.30K-208.8%
Q4 FY2024CQ1 2024Apr 30, 2024-$332.96K–
Q3 FY2024CQ4 2023Jan 31, 2024-$177.10K–
Q2 FY2024CQ3 2023Oct 31, 2023-$1.98M–
Q1 FY2024CQ2 2023Jul 31, 2023$342.96K–
Q4 FY2023CQ1 2023Apr 30, 2023-$288.39K–
Q3 FY2023CQ4 2022Jan 31, 2023-$541.70K–
Q2 FY2023CQ3 2022Oct 31, 2022-$1.88M–
Q1 FY2023CQ2 2022Jul 31, 2022-$1.08M–
Q4 FY2022CQ1 2022Apr 30, 2022-$1.19M–
Q3 FY2022CQ4 2021Jan 31, 2022-$298.65K–
Q2 FY2022CQ3 2021Oct 31, 2021-$1.39M–
Q1 FY2022CQ2 2021Jul 31, 2021-$1.24M–
Q4 FY2021CQ1 2021Apr 30, 2021-$940.30K–
Q3 FY2021CQ4 2020Jan 31, 2021-$589.13K–
Q2 FY2021CQ3 2020Oct 31, 2020-$1.25M–
Q1 FY2021CQ2 2020Jul 31, 2020-$551.00K–
Q4 FY2020CQ1 2020Apr 30, 2020-$639.39K–
Q3 FY2020CQ4 2019Jan 31, 2020-$352.22K–
Q2 FY2020CQ3 2019Oct 31, 2019-$583.63K–
Q1 FY2020CQ2 2019Jul 31, 2019-$763.14K–
Q4 FY2019CQ1 2019Apr 30, 2019-$661.36K–
Q3 FY2019CQ4 2018Jan 31, 2019-$676.50K–
Q2 FY2019CQ3 2018Oct 31, 2018-$917.81K–
Q1 FY2019CQ2 2018Jul 31, 2018-$622.24K–
Q4 FY2018CQ1 2018Apr 30, 2018-$1.37M–
Q3 FY2018CQ4 2017Jan 31, 2018-$1.17M–
Q2 FY2018CQ3 2017Oct 31, 2017-$1.60M–
Q1 FY2018CQ2 2017Jul 31, 2017-$935.57K–
Q4 FY2017CQ1 2017Apr 30, 2017-$800.89K–
Q3 FY2017CQ4 2016Jan 31, 2017-$925.30K–
Q2 FY2017CQ3 2016Oct 31, 2016-$706.35K–
Q1 FY2017CQ2 2016Jul 31, 2016-$906.93K–

More PharmaCyte Biotech figures

See a number that looks wrong?